Literature DB >> 7649575

Is white coat hypertension associated with arterial disease or left ventricular hypertrophy?

M C Cavallini1, M J Roman, T G Pickering, J E Schwartz, R Pini, R B Devereux.   

Abstract

Although white coat hypertension may be present in 20% or more of hypertensive individuals, its prognostic significance is unknown. We compared prognostically relevant measures of target-organ damage among 24 individuals with white coat hypertension and age- and sex-matched groups of sustained hypertensive and normotensive subjects classified by clinical and 24-hour ambulatory blood pressures. Left ventricular and carotid artery structure and function were evaluated by ultrasonography. Left ventricular mass index was similar in white coat hypertensive (82 +/- 17 g/m2) and normotensive (78 +/- 15 g/m2) subjects but was higher in sustained hypertensive subjects (97 +/- 19 g/m2, P < .02 and P < .002, respectively). Similarly, carotid artery intimal-medial thickness was greater in the sustained hypertensive group (0.98 +/- 0.21 mm) than in the white coat hypertensive (0.84 +/- 0.16 mm, P < .05) and normotensive (0.76 +/- 0.18 mm, P < .001) groups. The prevalence of discrete atherosclerotic plaques was higher in the sustained hypertensive group (58%) than in the white coat hypertensive (25%, P < .05) and normotensive (21%, P < .02) groups. Cardiac and carotid structure in individuals with white coat hypertension resemble findings in normotensive subjects and differ significantly from those in age- and sex-matched sustained hypertensive subjects. These findings suggest that white coat hypertension may be a benign condition for which pharmacological intervention may not be necessary, a hypothesis that needs to be tested in longitudinal studies with clinical end points.

Entities:  

Mesh:

Year:  1995        PMID: 7649575     DOI: 10.1161/01.hyp.26.3.413

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  13 in total

1.  Myocardial Performance Index in Childhood Onset Essential Hypertension and White Coat Hypertension.

Authors:  Monesha Gupta-Malhotra; Rabih K Hamzeh; Tim Poffenbarger; Karen McNiece-Redwine; Syed Shahrukh Hashmi
Journal:  Am J Hypertens       Date:  2015-08-12       Impact factor: 2.689

2.  Coronary flow reserve is preserved in white-coat hypertension.

Authors:  D Erdogan; H Gullu; M Caliskan; I Yildirim; D Tok; H Muderrisoglu
Journal:  Heart       Date:  2005-12-30       Impact factor: 5.994

Review 3.  Ambulatory blood pressure monitoring: a guide for general practitioners.

Authors:  N Prasad; C Isles
Journal:  BMJ       Date:  1996-12-14

Review 4.  Treatment of white coat hypertension.

Authors:  S G Chrysant
Journal:  Curr Hypertens Rep       Date:  2000-08       Impact factor: 5.369

5.  Microalbuminuria in children with primary and white-coat hypertension.

Authors:  Tomáš Seeman; Michael Pohl; Daniela Palyzova; Ulrike John
Journal:  Pediatr Nephrol       Date:  2011-10-05       Impact factor: 3.714

Review 6.  Ambulatory blood pressure monitoring.

Authors:  T G Pickering
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

7.  Prevalence and predictors of white-coat response in patients with treated hypertension.

Authors:  M B MacDonald; G P Laing; M P Wilson; T W Wilson
Journal:  CMAJ       Date:  1999-08-10       Impact factor: 8.262

8.  Changes in left ventricular structure and function in patients with white coat hypertension: cross sectional survey.

Authors:  M W Muscholl; H W Hense; U Bröckel; A Döring; G A Riegger; H Schunkert
Journal:  BMJ       Date:  1998-08-29

9.  Left ventricular mass index in children with white coat hypertension.

Authors:  Marc B Lande; Cecilia C Meagher; Susan Gross Fisher; Puneet Belani; Hongyue Wang; Megan Rashid
Journal:  J Pediatr       Date:  2008-03-19       Impact factor: 4.406

10.  Masked hypertensives: A disguised arterial stiffness population.

Authors:  Christina Antza; Ioannis Doundoulakis; Stella Stabouli; Konstantinos Tziomalos; Vasilios Kotsis
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-09-09       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.